NCT07187869View on ClinicalTrials.gov

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

April 7, 2027

Study Completion Date

April 7, 2029

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib

Given by IV

DRUG

Nivolumab

Given by IV

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT07187869 - Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | Biotech Hunter | Biotech Hunter